Advertisement


Gregory R. Pond, PhD, on Urothelial Cancer: Advance in Prognosis

2018 Genitourinary Cancers Symposium

Advertisement

Gregory R. Pond, PhD, of McMaster University, discusses a new six-factor prognostic model for patients with advanced urothelial carcinoma receiving post platinum atezolizumab (Abstract 413).



Related Videos

Solid Tumors

Jeffrey M. Holzbeierlein, MD, on Penile, Urethral, and Testicular Cancers: Abstract Roundup

Jeffrey M. Holzbeierlein, MD, of the University of Kansas Medical Center, summarizes key abstracts on long-term sexual function in germ cell tumor survivors, sentinel node biopsy i...

Prostate Cancer

Eric J. Small, MD, on Prostate Cancer: Results From the SPARTAN Trial

Eric J. Small, MD, of the University of California, San Francisco, discusses phase III findings on apalutamide vs placebo in patients with nonmetastatic castration-resistant prosta...

Bladder Cancer
Immunotherapy

Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Results From the CheckMate 032 Trial

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses longer-term efficacy and safety findings on nivolumab monotherapy in metastatic urothelial carcinoma...

Kidney Cancer

Patrick Schöffski, MD, MPH, on RCC: Final Results of the EORTC 90101 CREATE Trial

Patrick Schöffski, MD, MPH, of Catholic University Leuven, discusses findings on the effect of crizotinib on disease control in patients with advanced papillary renal cell carcinom...

Kidney Cancer

Daniel J. George, MD, on RCC: Results From the Alliance A031203 CABOSUN Trial

Daniel J. George, MD, of Duke University Medical Center, discusses study findings on cabozantinib vs sunitinib for previously untreated patients with advanced renal cell carcinoma ...

Advertisement

Advertisement



Advertisement